RYTM
NASDAQRhythm Pharmaceuticals Inc.
Price$113.35+0.34 (+0.31%)
01:30 PM07:45 PM
News · 26 weeks71+367%
2026-03-012026-08-23
Mix3390d
- Insider13(39%)
- Other6(18%)
- SEC Filings6(18%)
- Earnings5(15%)
- Leadership2(6%)
- Analyst1(3%)
Latest news
25 items- PRRhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization to IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO). IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received orphan d
- INSIDERSEC Form 4 filed by Chief Medical Officer Joshi Manher4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERSEC Form 3 filed by new insider Joshi Manher3 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERChief Technical Officer Shulman Joseph exercised 2,024 shares at a strike of $6.80 and sold $608,210 worth of shares (5,079 units at $119.75) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 15,915 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERChief Scientific Officer Garfield Alastair sold $912,703 worth of shares (7,763 units at $117.57) as part of a pre-agreed trading plan, decreasing direct ownership by 77% to 2,295 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- PRRhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical OfficerBOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher "AJ" Joshi, M.D., as Chief Medical Officer, effective August 17. "We are excited to welcome AJ to Rhythm as we enter a new stage of growth and continue to expand our global impact for patients living with rare neuroendocrine diseases," said David Meeker, M.D., Rhythm Chairman, President and Chief Executive Officer. "AJ brings more than two decades of leadership and experience from discovery through pivotal trials, global regu
- INSIDEREVP, Head of North America Lee Jennifer Kayden exercised 56,601 shares at a strike of $17.62 and sold $8,901,531 worth of shares (75,834 units at $117.38) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDEREVP, Head of International Mazabraud Yann exercised 46,625 shares at a strike of $6.80 and sold $6,620,575 worth of shares (57,000 units at $116.15) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 55,655 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- PRRhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or ImpairmentBOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger in adults and children 4 years of age and older with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment. The MHRA this week also granted IMCIVREE orphan drug designation for acquired HO. "This authorization marks an
- SECSEC Form 10-Q filed by Rhythm Pharmaceuticals Inc.10-Q - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- PRRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesBOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences. Hunter Smith will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026, 9:00 a.m. ET.David Meeker will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Bosto
- SECRhythm Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- PRRhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update-- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 net product revenue from global sales of IMCIVREE of $71.3 million ---- Weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in patients with acquired HO (n=7) after 16 weeks of treatment -- -- Phase 3 TRANSCEND Trial Results in Acquired HO published in the New England Journal of Medicine -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage b
- PRRhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon -- -- Management to host conference call to discuss second quarter 2026 financial results and business update today at 8:00 a.m. ET -- BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced preliminary results from the ongoing Phase 2 trial evaluating RM-718, Rhythm’s investigational once-weekly MC4R agonist, in patients with acquired hypothalamic obesity (HO). "These encour
- ANALYSTAnalyst initiated coverage on Rhythm Pharmaceuticals with a new price targetAnalyst initiated coverage of Rhythm Pharmaceuticals with a rating of Overweight and set a new price target of $145.00
- PRRhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A recording of the call will also be available under "Events and Presentations" in the Investo
- PRRhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic ObesityBOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM). The TRANSCEND study is the largest and longest placebo-controlled clinical trial ever conducted in patients with acquired hypothalamic obesity. The publication highlights robust improvements in weight and hunger achieve
- INSIDERChief Scientific Officer Garfield Alastair converted options into 4,445 shares and covered exercise/tax liability with 2,150 shares, increasing direct ownership by 30% to 10,058 units (SEC Form 4) to cover taxes4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Jean Christophe converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Mcgirr David W J converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Tetrault Lynn A. converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Arbuckle Stuart A converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Good Jennifer L converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- SECRhythm Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- INSIDERDirector Tetrault Lynn A. exercised 37,000 shares at a strike of $28.27 and sold $3,711,896 worth of shares (37,000 units at $100.32) as part of a pre-agreed trading plan (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
RYTM FAQ
7 questionsWhat does Rhythm Pharmaceuticals Inc. do?
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities...Where does RYTM stock trade?
Rhythm Pharmaceuticals Inc. (RYTM) is listed on NASDAQ.What sector and industry is RYTM in?
Rhythm Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rhythm Pharmaceuticals Inc. go public?
Rhythm Pharmaceuticals Inc. (RYTM) completed its IPO in 2017.What are analysts saying about RYTM?
Rhythm Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight on 2026-07-27.What companies are similar to RYTM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RYTM side-by-side with any of them on Quantisnow.How can I track RYTM on Quantisnow?
Quantisnow aggregates Rhythm Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RYTM to receive live email and push alerts on every new disclosure.